FT839 in Autoimmune Diseases
← catalyst calendarNCT07800871 · readout ≤ 789 d
Sponsored by Fate Therapeutics (industry) · FATE — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
446estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-09-02
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Oct 2026 | estimated | When the study began enrolling |
| Primary completion | Oct 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2040 | estimated | The whole study's end, after follow-up |
| First posted | 2026-09-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-09-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- ANCA-Associated Vasculitis (AAV)
- Idiopathic Inflammatory Myositis (IIM)
- Rheumatoid Arthritis (RA)
- Systemic Lupus Erythematosus (SLE)
- Systemic Sclerosis (SSc)
Intervention
- Biological: FT839
Primary outcomes
what the primary-completion date above is the date OFPhase 1: Incidence of Dose-limiting Toxicity, Adverse Events, and Serious Adverse Events
measured From enrollment to the end of the post-treatment follow-up at 2 years
Phase 2: Change from baseline in Birmingham Vasculitis Activity Score
measured From enrollment to the end of the post-treatment follow-up at 2 years
Phase 2: Change from baseline in Manual muscle testing-8
measured From enrollment to the end of the post-treatment follow-up at 2 years
Phase 2: Change from baseline in Disease Activity Score using 28 joint counts and C-reactive protein (a composite measure)
measured From enrollment to the end of the post-treatment follow-up at 2 years
Phase 2: Change from baseline in SLE Disease Activity Index 2000
measured From enrollment to the end of the post-treatment follow-up at 2 years
Phase 2: Change from baseline in Modified Rodnan skin score
measured From enrollment to the end of the post-treatment follow-up at 2 years
Related
FATE · their whole pipeline · Rheumatoid Arthritis readouts
FATE's other studiesmost recently updated first
- FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors Phase 1 · Recruiting
- A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis Phase 2 · Recruiting
- A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease Phase 1 · Recruiting
- FT819 in Subjects With B-cell Malignancies Phase 1 · Active, not recruiting
- FT576 in Subjects With Multiple Myeloma Phase 1 · Completed
Permalink · FATE's whole pipeline · Catalyst calendar · Every registered study · What changed